retatrutide trial safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Subcutaneous Fat Loss Results:

Choose high-fiber vegetables that are low in volume: spinach, green beans, and roasted broccoli pack significant fiber without the bulk of raw salads

Only 13 state Medicaid programs cover GLP-1 for obesity as of January 2026

Understanding this upfront helps you plan your treatment with a clear exit strategy

In research settings, often using a 10mg dose, Retatrutide is being tested to see how it affects metabolism and body weight

Its effect on total body fat, as opposed to visceral fat specifically, is also less pronounced than the GLP-1 class compounds

The unique metabolic profile of allulose differs from conventional sugars